Administration of cisplatin by inhalation

• US 20050249822A1
• Filed: 03/18/2005
• Published: 11/10/2005
• Est. Priority Date: 03/18/2004
• Status: Abandoned Application

• Current Assignee: Transave Inc. (Insmed Incorporated)
• Original Assignee: Transave Inc. (Insmed Incorporated)
• Inventors: Pilkiewicz, Frank G., Perkins, Walter, Metzheiser, Beth
• Application Number:
  US11/084,070
• Publication Number:
  US 20050249822A1
• Time in Patent Office: Days
• US Class Current: 424/649
• CPC Class Codes: A61K 31/282 Platinum compounds
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61K 33/243 Platinum; Compounds thereof
• CPC Class Codes: A61K 9/0078 for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

Provided is a method for treating a patient having lung cancer. The method includes administering a lipid composition containing cisplatin to the patient'"'"'s respiratory tract over the course of at least 2 treatment cycles. At least about 15 mg/m² of cisplatin is administered in each treatment cycle, and there is no more than 2 weeks between treatment cycles.

Claims

1. A method for treating a patient having cancer, comprising:

administering a lipid composition comprising cisplatin to the patient'"'"'s respiratory tract over the course of at least 2 treatment cycles, wherein;

at least about 15 mg/m² of cisplatin is administered in each treatment cycle; and

there is no more than 2 weeks between treatment cycles.

2. The method of claim 1, wherein there is no more than 1 week between treatment cycles.

3. The method of claim 1, wherein the method comprises at least 3 treatment cycles.

4. The method of claim 1, wherein the method comprises at least 4 treatment cycles.

5. The method of claim 1, wherein the method comprises at least 5 treatment cycles.

6. The method of claim 1, wherein the cisplatin to lipid ratio of the lipid composition is from about 1:

50 to about 1;

5 by weight.

7. The method of claim 6, wherein the cisplatin to lipid ratio of the lipid composition is from about 1:

50 to about 1;

10 by weight.

8. The method of claim 7, wherein the cisplatin to lipid ratio of the lipid composition is from about 1:

25 to about 1;

15 by weight.

9. The method of claim 1, wherein the lipid composition comprises DPPC.

10. The method of claim 1, wherein the lipid composition comprises cholesterol.

11. The method of claim 1, wherein the lipid component of the lipid composition comprises from about 50 to about 65 mol % of DPPC and about 35 to about 50 mol % cholesterol.

12. The method of claim 1, wherein the lipid composition further comprises an aqueous component.

13. The method of claim 12, wherein there is at least 80% by weight of the aqueous component in the lipid composition.

14. The method of claim 1, wherein the lipid composition is administered as an aerosol.

15. The method of claim 14, wherein the lipid composition is administered with a nebulizer at a flow rate of at least about 0.15 mL/min.

16. The method of claim 1, wherein the lipid composition comprises one or more liposomes.

17. The method of claim 1, wherein the cancer is a lung cancer.

18. The method of claim 17, wherein the lung cancer is selected from the group consisting of bronchoalveolar carcinoma and carcinomatosis with lymphangitic spread.

19. The method of claim 18, wherein the lung cancer is bronchoalveolar carcinoma.

20. A method for treating a patient having bronchoalveolar carcinoma, comprising:

administering a lipid composition comprising cisplatin to the patient'"'"'s respiratory tract over the course of at least 5 treatment cycles, wherein;

at least about 15 mg/m² of cisplatin is administered in each treatment cycle;

there is no more than 2 weeks between treatment cycles;

the lipid composition comprises from about 50 to about 65 mol % of DPPC and about 35 to about 50 mol % cholesterol; and

the cisplatin to lipid ratio is from about 1;

25 to about 1;

15 by weight.

21. The method of claim 20, wherein the lipid composition further comprises at least 80% by weight of aqueous component and the lipid composition is administered with a nebulizer.

22. The method of claim 21, wherein lipid composition is administered with a nebulizer at a flow rate of at least about 0.15 mL/min.